Abstract
Objective: The objective of the study is to systematically analyze and summarize research literature regarding health service use and costs of depressive symptoms in late life. Design: Relevant articles were identified by systematically searching the databases MEDLINE, Web of Science, PSYNDEXplus, PsycINFO, and Cochrane Library. Keywords were ‘depression’ or ‘depressive*’, and ‘cost’ or ‘economic burden’ or ‘utilization’ or ‘use’ and ‘old age’ or ‘elderly’. Studies based on representative samples of elderly individuals aged 55 years and older were included. Results: 55 studies were found, 34 studies determined health service utilization, 10 studies reported costs, and 11 studies reported both. Studies of health service utilization and costs showed homogeneously that depressive elderly individuals have an increased service use compared to non-depressive, and a one-third increase of outpatient, inpatient, and total healthcare costs of depressive individuals. The majority of studies reported antidepressant (AD) use between 20 and 45% by depressive individuals. Mean annual costs for AD ranged from 108 to 305 US$ PPP (purchasing power parities). Increased service use and costs are only to a small proportion related to depression treatment. Conclusions: Depressive symptoms in late life lead to a high economic burden for nations which is not explained by costs for depressive symptom treatment. Strategies for improvement of diagnostic validity and treatment success of depressive symptoms in late life may have an effect on economic burden for societies.
Keywords: Depression, depressive symptoms, health service use, utilization, economic burden, cost-of-illness, review, databases, elderly, antidepressant (AD)
Current Pharmaceutical Design
Title:Health Service Utilization and Costs of Depressive Symptoms in Late Life - A Systematic Review
Volume: 18 Issue: 36
Author(s): Melanie Luppa, Claudia Sikorski, Tom Motzek, Alexander Konnopka, Hans-Helmut Konig and Steffi G. Riedel-Heller
Affiliation:
Keywords: Depression, depressive symptoms, health service use, utilization, economic burden, cost-of-illness, review, databases, elderly, antidepressant (AD)
Abstract: Objective: The objective of the study is to systematically analyze and summarize research literature regarding health service use and costs of depressive symptoms in late life. Design: Relevant articles were identified by systematically searching the databases MEDLINE, Web of Science, PSYNDEXplus, PsycINFO, and Cochrane Library. Keywords were ‘depression’ or ‘depressive*’, and ‘cost’ or ‘economic burden’ or ‘utilization’ or ‘use’ and ‘old age’ or ‘elderly’. Studies based on representative samples of elderly individuals aged 55 years and older were included. Results: 55 studies were found, 34 studies determined health service utilization, 10 studies reported costs, and 11 studies reported both. Studies of health service utilization and costs showed homogeneously that depressive elderly individuals have an increased service use compared to non-depressive, and a one-third increase of outpatient, inpatient, and total healthcare costs of depressive individuals. The majority of studies reported antidepressant (AD) use between 20 and 45% by depressive individuals. Mean annual costs for AD ranged from 108 to 305 US$ PPP (purchasing power parities). Increased service use and costs are only to a small proportion related to depression treatment. Conclusions: Depressive symptoms in late life lead to a high economic burden for nations which is not explained by costs for depressive symptom treatment. Strategies for improvement of diagnostic validity and treatment success of depressive symptoms in late life may have an effect on economic burden for societies.
Export Options
About this article
Cite this article as:
Luppa Melanie, Sikorski Claudia, Motzek Tom, Konnopka Alexander, Konig Hans-Helmut and G. Riedel-Heller Steffi, Health Service Utilization and Costs of Depressive Symptoms in Late Life - A Systematic Review, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523572
DOI https://dx.doi.org/10.2174/138161212803523572 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Social Functioning Across the Course of Schizophrenia
Current Psychiatry Reviews Multivariate Analysis of Magnetic Resonance Imaging Signals of the Human Brain
Current Topics in Medicinal Chemistry Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics
Current Drug Discovery Technologies Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV<sub>1</sub>) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia
Current Neurovascular Research Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
Current Alzheimer Research Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Developing Novel Therapeutic Approaches to Frailty
Current Pharmaceutical Design Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Sleep, Depression and Insomnia – A Vicious Circle?
Current Psychiatry Reviews Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews Neuroprotective and Neurotoxic Implications of α7 Nicotinic Acetylcholine Receptor and Aβ Interaction: Therapeutic Options in Alzheimer's Disease
Current Drug Targets Non-Globular Structures of Tandem Repeats in Proteins
Protein & Peptide Letters The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Pathways of Acetylcholine Synthesis, Transport and Release as Targets for Treatment of Adult-Onset Cognitive Dysfunction
Current Medicinal Chemistry Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage
Current Alzheimer Research